Trends in the availability and prices of quality-assured tuberculosis drugs: a systematic analysis of Global Drug Facility Product Catalogs from 2001 to 2024.

Stefan Kohler Jay Achar Christiaan Mulder Norman Sitali Nicolas Paul

Published in: Globalization and health (2024)

The number of TB drugs available from the GDF has substantially increased during its first 23 years of operation. The prices of most APIs for new TB treatments decreased or remained stable. The prices of most APIs for standard drug-sensitive TB treatment increased.

Keyphrases

mycobacterium tuberculosis
drug induced
adverse drug
pulmonary tuberculosis
emergency department
quality improvement
hiv aids
antiretroviral therapy